Clinical Trial Update: Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency) [Phase 1, Phase 2]

View source ↗

Summary

The trial update for Sarepta's SRP-9003 gene therapy for limb-girdle muscular dystrophy type 2E shows the Phase 1/2 study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limb-girdle Muscular Dystrophy Type 2e

Drugs mentioned

• Bidridistrogene Xeboparvovec (SRP-9003)

Snippet

Sponsor: Sarepta Therapeutics, Inc. | Conditions: Limb-Girdle Muscular Dystrophy, Type 2E | Phase 1, Phase 2 | Status: TERMINATED